Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2008 2
2009 1
2010 2
2011 1
2012 3
2013 3
2015 4
2016 1
2017 1
2018 2
2019 3
2020 5
2021 3
2022 1
2023 2
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis.
Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Miyazaki T, Aotsuka N, Gotoh M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Tachibana T, et al. Transplant Cell Ther. 2021 Jan;27(1):70.e1-70.e8. doi: 10.1016/j.bbmt.2020.09.025. Epub 2020 Sep 30. Transplant Cell Ther. 2021. PMID: 33007494 Free article.
Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy.
Tanaka M, Kanamori H, Matsumoto K, Tachibana T, Numata A, Ohashi K, Kobayashi T, Nakaseko C, Kanda Y, Yamazaki E, Fujisawa S, Ooi J, Sakura T, Aotsuka N, Onoda M, Machida S, Kato J, Usuki K, Watanabe R, Taguchi J, Yano S, Saito T, Takahashi S, Sakamaki H, Okamoto S; Kanto Study Group for Cell Therapy. Tanaka M, et al. Bone Marrow Transplant. 2015 May;50(5):727-33. doi: 10.1038/bmt.2015.17. Epub 2015 Mar 2. Bone Marrow Transplant. 2015. PMID: 25730191 Clinical Trial.
[Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy].
Hagihara M, Kanamori H, Sakai M, Mori T, Nakaseko C, Aotsuka N, Uehara T, Sakura T, Yoshiba F, Kawai N, Tanaka M, Fujisawa S, Ohwada C, Wakita H, Yokota A, Kawamura T, Maruta A, Sakamaki H, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Hagihara M, et al. Rinsho Ketsueki. 2010 Jun;51(6):390-7. Rinsho Ketsueki. 2010. PMID: 20622484 Japanese.
Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study.
Kako S, Kanda Y, Onizuka M, Aotsuka N, Usuki K, Tachibana T, Kobayashi T, Kato J, Yano S, Shimizu H, Shono K, Tanaka M, Tsukamoto S, Mori T, Yamazaki E, Najima Y, Hangaishi A, Hoshino T, Watanabe R, Matsumoto K, Okamoto S; for Kanto Study Group for Cell Therapy (KSGCT). Kako S, et al. Am J Hematol. 2020 Mar;95(3):251-257. doi: 10.1002/ajh.25693. Epub 2019 Dec 19. Am J Hematol. 2020. PMID: 31804748 Free article. Clinical Trial.
Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).
Tachibana T, Kanda J, Machida S, Saito T, Tanaka M, Najima Y, Koyama S, Miyazaki T, Yamamoto E, Takeuchi M, Morita S, Kanda Y, Kanamori H, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Tachibana T, et al. Int J Hematol. 2018 May;107(5):578-585. doi: 10.1007/s12185-017-2396-9. Epub 2018 Jan 5. Int J Hematol. 2018. PMID: 29305770 Clinical Trial.
A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation.
Kanda Y, Kobayashi T, Mori T, Tanaka M, Nakaseko C, Yokota A, Watanabe R, Kako S, Kakihana K, Kato J, Tanihara A, Doki N, Ashizawa M, Kimura SI, Kikuchi M, Kanamori H, Okamoto S; Kanto Study Group for Cell Therapy. Kanda Y, et al. Bone Marrow Transplant. 2016 Jan;51(1):103-9. doi: 10.1038/bmt.2015.222. Epub 2015 Oct 5. Bone Marrow Transplant. 2016. PMID: 26437063 Clinical Trial.
Allogeneic hematopoietic stem cell transplantation for patients with mildly reduced renal function as defined based on creatinine clearance before transplantation.
Oshima K, Kanda Y, Nanya Y, Tanaka M, Nakaseko C, Yano S, Fujisawa S, Fujita H, Yokota A, Takahashi S, Kanamori H, Okamoto S; Kanto Study Group for Cell Therapy. Oshima K, et al. Ann Hematol. 2013 Jan;92(2):255-60. doi: 10.1007/s00277-012-1584-1. Epub 2012 Oct 4. Ann Hematol. 2013. PMID: 23053182
Clinical significance of late CMV disease in adult patients who underwent allogeneic stem cell transplant.
Shimizu H, Najima Y, Kako S, Tanaka M, Fujiwara SI, Mori T, Usuki K, Gotoh M, Hagihara M, Tsukada N, Oniduka M, Takada S, Sakaida E, Fujisawa S, Onoda M, Aotsuka N, Yano S, Ohashi K, Takahashi S, Okamoto S, Kanda Y; Kanto Study Group for Cell Therapy (KSGCT). Shimizu H, et al. J Infect Chemother. 2023 Dec;29(12):1103-1108. doi: 10.1016/j.jiac.2023.07.015. Epub 2023 Aug 1. J Infect Chemother. 2023. PMID: 37532223
25 results